Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

Discussion In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.

http://nn.neurology.org/cgi/content/short/9/4/e1178?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - May 6, 2022 Category: Neurology Authors: Palomares Cabeza, V., Kummer, L. Y. L., Wieske, L., Hagen, R. R., Duurland, M., Konijn, V. A. L., van Dam, K. P. J., Stalman, E. W., van de Sandt, C. E., Boekel, L., Verstegen, N. J. M., Steenhuis, M., Rispens, T., Tas, S. W., Wolbink, G., Killestein, J., Tags: Autoimmune diseases, COVID-19, Multiple sclerosis Clinical/Scientific Note Source Type: research